Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SERS-based Technology for EarLy Liquid biopsy Analysis and Recognition

Project description

New tech to improve cancer diagnostics

MicroRNA (miRNA)-based cancer diagnostics are becoming essential for early cancer detection. However, their use is often limited by high costs, lengthy processing times, and the requirement for specialised equipment and personnel. The ERC-funded STELLAR project will revolutionise early cancer detection using surface-enhanced Raman spectroscopy (SERS) and AI to analyse miRNA in liquid biopsies. This non-invasive, cost-effective method will accurately differentiate between normal and mutated miRNAs, even at the level of single-nucleotide polymorphisms, without requiring expensive and complex sequencing technologies. With novel miRNA isolation, a SERS detection platform, and AI data analysis, the project will improve cancer screening, enhance patient outcomes, and reduce healthcare costs. The project will also prepare the technology for commercialisation.

Objective

STELLAR introduces a groundbreaking approach to early cancer detection, leveraging surface-enhanced Raman spectroscopy (SERS) and artificial intelligence (AI) to analyse microRNAs (miRNAs) in liquid biopsies. This innovative technology aims to revolutionize cancer screening by offering a non-invasive, cost-effective, and highly accurate method for identifying cancer-specific miRNA biomarkers. STELLAR's core innovation lies in its ability to detect and discriminate between normal and mutated miRNAs with exceptional accuracy, even at the level of single nucleotide polymorphisms, without the need for expensive and complex sequencing technologies. The project encompasses the development of a comprehensive system, including a novel miRNA isolation and enrichment method, a SERS-based detection platform utilizing silver nanoparticle-enhanced substrates, and an AI algorithm for data analysis. This integrated approach promises to overcome current limitations in miRNA-based cancer diagnostics, such as high costs, lengthy processing times, and the need for specialized equipment and personnel. STELLAR aims to progress from TRL 2/3 to TRL 4/5, validating the technology with clinical samples and establishing a clear path toward commercialization. The project's multifaceted strategy includes rigorous technical development, IP protection, regulatory planning, and market analysis. The project's success could significantly impact early cancer detection rates, improving patient outcomes and reducing healthcare costs. STELLAR's approach to combining SERS technology with AI-driven analysis opens new avenues for personalized medicine and could set new standards for AI-integrated medical devices. As the project progresses, it will explore various commercialization pathways, including the potential creation of a spin-out company or licensing agreements, with the goal of bringing this transformative technology to market and making a substantial impact on global health.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

POLITECNICO DI TORINO
Net EU contribution
€ 150 000,00
Address
CORSO DUCA DEGLI ABRUZZI 24
10129 Torino
Italy
Region
Nord-Ovest Piemonte Torino
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)